Insung Medical Co., Ltd. concludes a licensing agreement with Collagen Solutions for ‘ChondroMimetic’
Insung Medical Co., Ltd. recently announced that it has entered into a licensing agreement for ChondroMimetic with Collagen Solutions, a developer and manufacturer of medical collagen and tissue components used in regenerative medicine applications such as orthopedics, dentistry, wound and cardiovascular.
With the conclusion of this contract, Insung Medical is preparing to launch products through a diversified product range and sales route in the Korean market, and plans to apply for approval from the Ministry of Food and Drug Safety (MFDS) of Korea in parallel with applying for CE marking for European approval. . In addition, Collagen Solution expands its diverse range of biomaterial-based finished medical devices based on intellectual property rights through licensing and distribution agreements including Insung Medical and ChondroMimetic.
ChondroMimetic is a minimally invasive surgical method that can treat cartilage defects in the knee and was developed through many years of clinical research.
Collagen Solution is a global supplier/manufacturer and developer of medical collagen, tissue, and related medical devices and components for use in regenerative medicine, medical devices, in vitro diagnosis, and research. Its products include orthopedics, cardiovascular system, dentistry, plastic surgery, It is used in a variety of applications including wound care, neurology and urology.
Insung Medical Co., Ltd., located in Wonju Enterprise City, was established in 1993 and is a medical device specialized company that focuses on manufacturing and selling consumables and surgical medical device products in domestic and overseas markets.
“We are excited to announce our first partnership with Insung Medical and to capitalize on ChondroMimetic’s global commercial opportunity,” said Jamal Rushdy, CEO of Collagen Solutions. “We are pleased to provide initial verification of this,” he said. “I look forward to the future with Insung Medical to launch ChondroMimetic, which is simple, long-term, and cost-effective to solve the difficult problem of cartilage defects.”
※news report
-EHealthnews: https://www.e-healthnews.com/news/article_view.php?art_id=151107
Insung Medical Co., Ltd. concludes a licensing agreement with Collagen Solutions for ‘ChondroMimetic’
Insung Medical Co., Ltd. recently announced that it has entered into a licensing agreement for ChondroMimetic with Collagen Solutions, a developer and manufacturer of medical collagen and tissue components used in regenerative medicine applications such as orthopedics, dentistry, wound and cardiovascular.
With the conclusion of this contract, Insung Medical is preparing to launch products through a diversified product range and sales route in the Korean market, and plans to apply for approval from the Ministry of Food and Drug Safety (MFDS) of Korea in parallel with applying for CE marking for European approval. . In addition, Collagen Solution expands its diverse range of biomaterial-based finished medical devices based on intellectual property rights through licensing and distribution agreements including Insung Medical and ChondroMimetic.
ChondroMimetic is a minimally invasive surgical method that can treat cartilage defects in the knee and was developed through many years of clinical research.
Collagen Solution is a global supplier/manufacturer and developer of medical collagen, tissue, and related medical devices and components for use in regenerative medicine, medical devices, in vitro diagnosis, and research. Its products include orthopedics, cardiovascular system, dentistry, plastic surgery, It is used in a variety of applications including wound care, neurology and urology.
Insung Medical Co., Ltd., located in Wonju Enterprise City, was established in 1993 and is a medical device specialized company that focuses on manufacturing and selling consumables and surgical medical device products in domestic and overseas markets.
“We are excited to announce our first partnership with Insung Medical and to capitalize on ChondroMimetic’s global commercial opportunity,” said Jamal Rushdy, CEO of Collagen Solutions. “We are pleased to provide initial verification of this,” he said. “I look forward to the future with Insung Medical to launch ChondroMimetic, which is simple, long-term, and cost-effective to solve the difficult problem of cartilage defects.”
※news report
-EHealthnews: https://www.e-healthnews.com/news/article_view.php?art_id=151107